Loading clinical trials...
Loading clinical trials...
T Regulatory Cells in Lupus Nephritis
* To study the role FoxP3-positive T regulatory cells in the pathogenesis of Lupus Nephritis, and determine the factors associated with levels of T regs . * To compare the functional capacity of T regs in LN and in normal individuals.
Lupus Nephritis (LN) encompasses a group of glomerulonephrites, that occur in association with systemic lupus erythematosus (SLE). The mainstream theory that it is an immune disease resulting from loss of immune tolerance against body cells. The regulatory T cells (T regs ) are a subpopulation of immune cells that maintain tolerance to self-antigens and suppress autoimmune diseases. The main marker of Tregs is FoxP3 (forkhead box protein 3) positivity. Moreover, It has been suggested that functional capacity of Tregs is also compromised in autoimmune diseases. Studying the role of T regs in LN is a promising field that can help tailor current immune therapy and develop new treatment strategies.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
Yes
Start Date
July 1, 2024
Primary Completion Date
July 1, 2025
Completion Date
August 1, 2025
Last Updated
May 29, 2024
65
ESTIMATED participants
T-reg cells
DIAGNOSTIC_TEST
Lead Sponsor
Assiut University
NCT05126277
NCT07015983
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06947460